phase iib 144 wks

perhaps timely with 144 wk data presumably close/imminent

lets have those 96 week data for comparison

After 96 weeks of treatment, over 85% of patients continue to have HIV levels below detectable and all patients continue to receive ATC treatment. In addition, patients CD4 cells (cells that are normally destroyed by HIV)continued to increase in number over the 96 weeks.

The key highlights of the data are:
No resistance to ATC has been identified after 96 weeks of dosing
CD4 cells in patients continue to rise with ongoing ATC treatment
No ATC-related Serious Adverse Events
No withdrawals from the trial due to side effects associated with ATC
39 patients completed the 96 week treatment period